ArticleJournal of medical biochemistry2025
Serum CA125, CA199, estradiol, FSH, IL-6, TNF-a in endometriosis after administration of Tripterygium wilfordii glycosides.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the therapeutic effects of Tripterygium wilfordii glycosides on endometriosis (EMs) and their effects on serum sex hormone levels, tumour markers, and inflammatory factors (serum CA125, CA199, Estradiol, FSH, IL-6, TNF-a). Methods: A total of 108 patients were randomly divided into control, progesterone, and Tripterygium wilfordii glycoside-treated groups, each receiving treatment for three months. The clinical efficacy and serum levels of estradiol, follicle-stimulating hormone, tumour markers (cancer antigen125 and cancer antigen199), and pro-inflammatory cytokines were compared before and after treatment. Results: The Tripterygium wilfordii glycoside group exhibited a significantly higher clinically effective rate (90.74% versus 75.93%) and more significant reductions in estradiol, follicle-stimulating hormone, cancer antigen125, cancer antigen199, IL-6, TNF-a, and HSCRP levels than the control group. Conclusions: Tripterygium glycosides exhibit significant clinical efficacy in treating patients with EMS by significantly improving serum sex hormone levels, reducing tumour marker levels, alleviating inflammatory reactions, and exerting minimal toxic side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.